Biotechnology - Merck & Co


Current filters:

Merck & Co

Popular Filters

1 to 25 of 36 results

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market


Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

Merck & Co enters deal with Agenus worth a potential $100 million in milestones


USA-based biotech firm Agenus has entered into a collaboration and license agreement with pharma giant…

AgenusBiotechnologyLicensingMerck & CoOncologyResearch

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co


World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics


US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

First biosimilar monoclonal antibody approved in Europe


US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Bionomics in $172 million pain treatment deal with US pharma giant


Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

New Zealand consults on Victrelis listing and some Pegasys amendments


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children


In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy


US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Cerecor acquires rights to NR2B receptor antagonist from Merck & Co


Privately-held US neuroscience biotech firm Cerecor says that it has acquired exclusive, worldwide rights…

BiotechnologyCerecorLicensingMerck & CoMK-0657Neurological

Zymeworks gets second milestone from Merck & Co under Azymetric platform accord


Privately-held Canadian biotech firm Zymeworks announced the successful achievement of a second research…

Azymetric platformBiotechnologyLicensingMerck & CoPharmaceuticalResearchZymeworks

Cerecor acquires rights to Merck & Co's COMT inhibitors


US neuroscience biotech company Cerecor has acquired exclusive, worldwide rights to develop, register…

BiotechnologyCerecorLicensingMerck & CoNeurologicalPharmaceutical

Merck & Co in biosimilars deal with Samsung Bioepis


US pharma giant Merck & Co (NYSE: MRK) has entered into an agreement with South Korea-based Samsung Bioepis…

Biogen IdecBiotechnologyMerck & CoPharmaceuticalProductionResearchSamsung Bioepis

Merck & Co and Gilead highlight new data at international HIV meeting


US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

ASBMR 2012: Anabolics and post-marketing studies


This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting


Amgen (Nasdaq: AMGN), the world's largest biotech firm, has presented data from several Prolia (denosumab)…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMerck & CoodanacatibPharmaceuticalProliaResearchWomen's Health

1 to 25 of 36 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top